HealthLumen Blog
New genetic database analysis finds that Fabry disease may be three times more prevalent than current estimates suggest, uncovering a large underserved patient community
Fabry disease is a rare genetic X-linked disease caused by pathogenic genetic variants in the GLA gene. As with other rare genetic conditions, of which there are thought to be over 7000, accurately determining the prevalence of Fabry disease is challenging. Using HealthLumen’s genetic database mining methodology, our recent study suggests that Fabry disease prevalence in the US may considerably exceed previous estimates.
Read
Beyond weight loss: The potential of GLP-1 receptor agonists to reduce the prevalence of obesity-related diseases
Addressing growing rates of obesity and its increasing strain on healthcare systems has become a key focus for many public health strategies around the globe. As part of the evolving landscape of obesity interventions, GLP-1 receptor agonists (commonly referred to as GLP-1 agonists) have emerged as a promising pharmacological solution. But how effective are GLP-1 agonists as part of a broader public health obesity strategy?
Read
NEWS: England faces £1.2 billion in healthcare costs if Covid-19 lockdown alcohol consumption trends persist to 2035
When the Covid-19 pandemic hit in early 2020, drinking habits shifted significantly for many. But what happens when those pandemic-era drinking habits stick around? Recent research from HealthLumen explores the long-term consequences of changes in alcohol consumption during the pandemic, and the findings are stark: if those patterns continue until the end of 2035, England could face nearly 10,000 additional premature deaths, over 147,000 excess cases of disease, and £1.2 billion extra in healthcare costs.
Read
Demonstrating the value of cascade screening using microsimulation modelling: A pathway to faster diagnosis and improved patient outcomes for genetic diseases
Earlier diagnosis can make all the difference for individuals with genetic diseases. Delayed diagnosis hinders timely disease management and treatment access, meaning that progression to late-stage disease can occur more rapidly, likely leading to a significant increase in the health and economic burden of these conditions for patients, their families, and healthcare systems. Screening programs aim to identify individuals with genetic conditions earlier, with cascade screening in particular providing one way to help transform outcomes for patients.
Read